Chief Technology Officer · FATE THERAPEUTICS INC (FATE)

Mark Plavsic

FY2021 is the first fiscal year CompBrief holds for Mark Plavsic as a named executive officer of FATE THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$8,379,027

Salary $230,137Stock awards $6,915,474

2nd of 6 named executive officers at Fate Therapeutics by FY2021 total.

6 named officers on file for FATE THERAPEUTICS, FY2021

Mark Plavsic’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • FATE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how FATE THERAPEUTICS’s whole pay program stands against its peers

  • FATE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FATE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Mark Plavsic’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark Plavsic compensation by year

FATE THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as FATE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$230,137
Stock awards$6,915,474
Option awards$993,361
Non-equity incentive$92,055
Pension and deferred compensation$0
All other$148,000
Total$8,379,027

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: FATE THERAPEUTICS INC DEF 14A filed April 25, 2022, accession 0001193125-22-117516, and prior-year filings. Open the filing on EDGAR.

How this page was built: the FATE THERAPEUTICS INC filed document, accession 0001193125-22-117516. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU59,540$3,483,685—
RSU38,000$2,223,380—
Option18,500—$89.97

Per the Outstanding Equity Awards at Fiscal Year-End table in FATE THERAPEUTICS INC's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 25, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-01-10Sale—3,418$5.24123,705

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

FATE THERAPEUTICS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
J. Scott WolchkoPresident, Chief Executive Officer and Director$11,728,617
Mark Plavsic · this pageChief Technology Officer$8,379,027
Bahram ValamehrChief Research and Development Officer$6,477,416
Yu-Waye ChuChief Medical Officer(7)$6,477,416
Cindy TahlGeneral Counsel and Corporate Secretary$6,477,416
Edward DulacChief Financial Officer(4)$6,384,051

The full FATE THERAPEUTICS compensation record

free company brief

This page is one person within FATE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the FATE THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are FATE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Plavsic's compensation dossier · One-time report. No refunds.